News | March 19, 2024
Grace expands CDMO capacity by 25% of South Haven facility in Michigan
Additional capacity broadens Grace’s fine chemical capabilities for API production
Additional capacity broadens Grace’s fine chemical capabilities for API production
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
The validations confirm the completion of the applications and commence the scientific review process
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Both the Ministries signed MoU for anaemia control among adolescent girls using Ayurveda interventions
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Subscribe To Our Newsletter & Stay Updated
